EGFR and non-small cell lung carcinoma: Exon 19 deletions (Del19) and epidermal growth factor receptor (EGFR) exon 21 p.L858R mutations account for approximately 45% and 40% of the cases of epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC).